PDF herunterladen
Thromb Haemost 1997; 78(01): 566-570
DOI: 10.1055/s-0038-1657590
New treatments of von Wiltebrand disease
Schattauer GmbH Stuttgart

New Treatments of von Willebrand Disease: Plasma Derived von Willebrand Factor Concentrates

Doris Menache
1   Biomedical Services, American Red Cross, Washington, DC, USA
,
David L Aronson
2   Division of Hematology, George Washington University, Washington, DC, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints
 

  • References

  • 1 Blatt PM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand disease: Dissociation of bleeding-time factor and ristocetin-cofactor activities. J Am Med Ass 1976; 236: 2770-2772
    CrossrefPubMedGoogle Scholar
  • 2 Green D, Potter V E. Failure of AHF concentrate to control bleeding in von Willebrand’s disease. Am J Med 1976; 60: 357-360
    CrossrefPubMedGoogle Scholar
  • 3 Bennett E, Dormandy K. Pool’s cryoprecipitate and exhausted plasma in the treatment of von Willebrand’s disease and factor-XI deficiency. Lancet 1966; 731-732
    PubMedGoogle Scholar
  • 4 Bumouf-Rasedovich M, Bumouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang 1992; 62: 01-11
    CrossrefPubMedGoogle Scholar
  • 5 Lawrie AS, Harrison P, Armstrong AL, Wilbourn BR, Dalton RG, Savidge GF. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates. Br J Haematol 1989; 73: 100-104
    CrossrefPubMedGoogle Scholar
  • 6 Fricke AW, Yu MW. Characterization of von Willebrand factor in factor VIII concentrates. Am J Hematol 1989; 31: 41-45
    CrossrefPubMedGoogle Scholar
  • 7 Morfini M, Rafanelli D, Filimberti E, Cinotti S, Piazza E, Longo G, Ferrini PR. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates. Thromb Res 1989; 56: 169-178
    CrossrefPubMedGoogle Scholar
  • 8 Mazurier C, Jorieux S, de Romeuf C, Samor B, Goudemand M. In vitro evaluation of a veiy-high-purity, solvent/detergent treated, von Willebrand factor concentrate. Vox Sang 1991; 61: 1-7
    CrossrefPubMedGoogle Scholar
  • 9 Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A cross-over randomized trial. Blood 1992; 79: 3130-3137
    CrossrefPubMedGoogle Scholar
  • 10 Bemtorp E. Plasma product treatment in various types of von Willebrand’s disease. Haemostasis 1994; 24: 289-297
    PubMedGoogle Scholar
  • 11 Mannucci PM, Chediak J, Byrnes J, Kessler C, Marciniak E, Hanna W, Retzios AD. and the Alphanate study Group. A high purity factor VIII concentrate in the treatment of von Willebrand’s disease. Presented at the XXII International Congress of the World Federation of Hemophilia Dublin; Ireland: 1996
    Google Scholar
  • 12 Weinstein M, Deykin D. Comparison of factor VUI-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate. Blood 1979; 53: 1095-1105
    PubMedGoogle Scholar
  • 13 Mannucci PM, Moia M, Rebulla P, Altieri D, Monteagudo J, Castillo R. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987; 25: 55-65
    CrossrefPubMedGoogle Scholar
  • 14 Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994; 83: 3018-3027
    PubMedGoogle Scholar
  • 15 Menache D, Aronson DL, Darr F, Montgomery RR. and The Cooperative Study Group. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Br J Haematol 1996; 94: 740-745
    CrossrefPubMedGoogle Scholar
  • 16 Weiss HJ. Relation of von Willebrand factor to bleeding time. (Letter) N Engl J Med 1974; 291: 420
    PubMedGoogle Scholar
  • 17 Castillo R, Monteagudo J, Escolar G, Ordinas A, Magallon M, Villar JM. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 1991; 77: 1901-1905
    PubMedGoogle Scholar
  • 18 Boda Z, Pfliegler G, Harsfolvi J, Rak K. Treatment of the severe bleeding episode in type III von Willebrand’s disease by simultaneous administration of cryoprecipitate and platelet concentrate. Blood Coagul Fibrinolysis 1991; 2: 775-777
    CrossrefPubMedGoogle Scholar
  • 19 Ramstrom G, Blomback M, Egberg N, Johnsson H, Ljungberg B, Schulman S. Oral surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985). Int J Oral Maxillofac Surg 1989; 18: 320-322
    CrossrefPubMedGoogle Scholar
  • 20 Bloom AL, Peake IR, Furlong RA, Davies BL. High potency factor VIII concentrate: more effective than cryoprecipitate in a patient with von Willebrand’s disease and inhibitor. Thromb Res 1979; 16: 847-852
    CrossrefPubMedGoogle Scholar
  • 21 Hathaway WE, Mahasandana C, Clarke S, Humbert JR. Paradoxical bleeding in intensively transfused hemophiliacs: Alteration of platelet function. Transfusion 1973; 13: 06-12
    CrossrefPubMedGoogle Scholar
  • 22 Halvorson EP, Hildgartner MW. Transient acquired defect in platelet function following therapy with AHF concentrate. Mt Sinai J Med 1978; 45: 282-287
    PubMedGoogle Scholar
  • 23 Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: Results of an international survey. On behalf of the subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 784-790
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Foster PA. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: Results on an international survey. On behalf of the subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1370-1378
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 25 Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193-199
    PubMedGoogle Scholar
  • 26 Kohler M, Hellstem P, Wenzel E. The use of heat-treated factor VIII concentrates in von Willebrand’s disease. Blut 1985; 50: 25-27
    CrossrefPubMedGoogle Scholar
  • 27 Fukui H, Nishino M, Terada S, Nishikubo T, Yoshioka A, Kinoshita S, Niinomi K, Yoshioka K. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate-P) in von Willebrand’s disease. Blut 1988; 56: 171-178
    CrossrefPubMedGoogle Scholar
  • 28 Berntorp E, Nilson IM. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand’s disease. Vox Sang 1989; 56: 212-217
    PubMedGoogle Scholar
  • 29 Ieko M, Sakurama S, Sagawa A, Yoshikawa M, Satoh M, Yasukouchi T, Nakagawa S. Effect of factor VIII concentrate on type IIB von Willebrand’s disease-associated thrombocytopenia presenting during pregnancy in identical twin mothers. Am J Hematol 1990; 35: 26-31
    CrossrefPubMedGoogle Scholar
  • 30 Scharrer I, Vigh T, Aygoren-Pursun E. Experience with Haemate P in von Willebrand’s disease in adults. Haemostasis 1994; 24: 298-303
    PubMedGoogle Scholar
  • 31 Kreuz W, Mentzer D, Becker S, Scharrer I, Komhuber B, Haemate P. in children with von Willebrand’s disease. Haemostasis 1994; 24: 304-310
    PubMedGoogle Scholar
  • 32 Cumming AM, Fildes S, Cumming IR, Wensley RT, Redding OM, Bum AM. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand’s disease. Br J Haematol 1990; 75: 234-239
    CrossrefPubMedGoogle Scholar
  • 33 Pasi KJ, Williams MD, Enayat MS, Hill FGH. Clinical and laboratory evaluation of the treatment of von Willebrand’s disease patients with heat-treated factor VIII concentrate (BPL 8Y). Brit J Haematol 1990; 75: 228-233
    CrossrefPubMedGoogle Scholar
  • 34 Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickies FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost 1994; 71: 173-179
    PubMedGoogle Scholar
  • 35 Mannucci PM, Chediak J, Byrnes J, Kessler C, Marciniak E, Hanna W, Retzios AD. and the Alphanate study Group A high purity factor VIII concentrate in the treatment of von Willebrand’s disease. Blood 1996; (Suppl. 088) 1: 1309 (abst)
    PubMedGoogle Scholar
  • 36 Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M. Clinical and biological evaluation in von Willebrand’s disease of a von Willebrand factor concentrate with low factor VIII activity. Brit J Haematol 1992; 80: 214-221
    CrossrefPubMedGoogle Scholar
  • 37 Scott JP, Montgomery RR. Therapy of von Willebrand disease. Semin Thromb Hemost 1993; 19: 37-47
    Artikel in Thieme ConnectPubMedGoogle Scholar